Differentiation potential of adult human mesenchymal stem cells.
Pansky A., Roitzheim B., Tobiasch E.
Laboratory Study, published in Clin Lab (2007) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Laboratory Study
- Journal
- Clin Lab (2007)
- Country
- Germany
- Reported sample size
- —
- Source database
- PubMed
- PMID
- 17323830
Abstract (original English)
Human mesenchymal stem cells (HMSCs) which are isolated from bone marrow stroma, peripheral blood, dermis, muscle and adipose tissue have the advantage of potential autologous transplantation ability. They can be differentiated into chondrogenic, osteogenic, adipogenic and myogenic lineages. Problems of stem cells from bone marrow are low cell numbers, low isolated volumes, pain, and to some extent ethical concerns. The isolation of mesenchymal stem cells from human adipose tissue was recently identified as an alternative source, since these cells are easy to obtain in big cell numbers. Adipose tissue is derived from embryonic mesoderm and contains a heterogeneous stromal cell population. To achieve lineage-specific differentiation of these cells they have to be cultured in media supplemented with appropriate factors. Inductions of the cells into multiple mesenchymal lineages resulted in the expression of several lineage-specific genes, proteins and specific metabolic activity. In conclusion, the potential benefit of the multi-germline capacity of HMSCs seems to be a promising approach for allogenic cell therapy and human tissue engineering.
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is preclinical work; animal or laboratory results cannot be applied to humans.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.